Advertisement

Japanese Journal of Ophthalmology

, Volume 53, Issue 4, pp 389–395 | Cite as

One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups

  • Seungbum Kang
  • Young-Jung Roh
Clinical Investigation

Abstract

Purpose

To report 1-year clinical outcomes of intravitreal ranibizumab treatment for choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) and to identify predictive factors that may influence visual acuity (VA) outcomes in Korean patients.

Methods

Sixty patients (64 eyes) with subfoveal CNV were followed up over 12 months after intravitreal injection (0.5 mg) of ranibizumab at baseline and subsequent injections on an as-needed basis. The VA outcomes over 12 months were compared with baseline VA and evaluated across subgroups based on sex, age, baseline VA, CNV size, CNV type, and presence or absence of systemic disease and prior photodynamic therapy.

Results

VA improved or remained stable in 46 of 64 eyes (71.9%) at 12 months. Subgroup analysis showed that both baseline VA and CNV size influenced VA outcomes after ranibizumab treatment (P = 0.039, P = 0.042, respectively). However, the patients’ sex (P = 0.643), baseline age (P = 0.361), CNV type (P = 0.940), and the presence or absence of systemic disease (P = 0.775) and prior photodynamic therapy (P = 0.890) did not affect VA outcomes.

Conclusions

Intravitreal injections of ranibizumab improve mean VA in patients with subfoveal CNV secondary to AMD, and baseline VA and CNV lesion size were predictive factors of VA outcomes after ranibizumab treatment in Korean patients.

Key Words

neovascular age-related macular degeneration ranibizumab subgroup analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;107:1640–1642.Google Scholar
  2. 2.
    Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996;122:393–403.PubMedGoogle Scholar
  3. 3.
    Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929–1934.PubMedGoogle Scholar
  4. 4.
    Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3186–3193.PubMedCrossRefGoogle Scholar
  5. 5.
    Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111–118.PubMedCrossRefGoogle Scholar
  6. 6.
    Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40:352–368.PubMedGoogle Scholar
  7. 7.
    Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850–857.PubMedCrossRefGoogle Scholar
  8. 8.
    Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805–2816.PubMedCrossRefGoogle Scholar
  9. 9.
    Cleary CA, Jungkim S, Ravikumar K, et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6 and 9 month results. Eye 2008;22:82–86.PubMedCrossRefGoogle Scholar
  10. 10.
    Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med 2006;355:1419–1431.CrossRefGoogle Scholar
  11. 11.
    Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Eng J Med 2006;355:1432–1444.CrossRefGoogle Scholar
  12. 12.
    Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566–583.PubMedCrossRefGoogle Scholar
  13. 13.
    Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008;145:249–256.PubMedCrossRefGoogle Scholar
  14. 14.
    Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246–252.PubMedCrossRefGoogle Scholar
  15. 15.
    Byeon SH, Lee SC, Oh HS, et al. Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. Jpn J Ophthalmol 2008;52:57–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Ichiro Maruko, Tomohiro Iida, Masaaki Saito, et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144:15–22.PubMedCrossRefGoogle Scholar
  17. 17.
    Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group, Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to agerelated macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003;136:407–418.CrossRefGoogle Scholar
  18. 18.
    Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Arch Ophthalmol 1999;117:1329–1345.Google Scholar
  19. 19.
    Fraser-Bell S, Wu J, Klein R, et al. Cardiovascular risk factors and age-related macular degeneration: the Los Angeles Latino Eye Study. Am J Ophthalmol 2008;145:308–316.PubMedCrossRefGoogle Scholar
  20. 20.
    Tan JS, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2007;114:1143–1150.PubMedCrossRefGoogle Scholar
  21. 21.
    Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 2003;110:636–643.PubMedCrossRefGoogle Scholar
  22. 22.
    Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239–248.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Ophthalmological Society (JOS) 2009

Authors and Affiliations

  1. 1.Department of Ophthalmology and Visual Sciences, College of MedicineThe Catholic University of KoreaSeoulKorea
  2. 2.Department of Ophthalmology, St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulKorea

Personalised recommendations